Drug Release/Dissolution Specifications To Be Discussed By Advisory Committee
This article was originally published in The Pink Sheet Daily
Advisory Committee for Pharmaceutical Science will also discuss pharmaceutical equivalence and product design at May 3-4 meeting. Committee will receive updates on activities of the Clinical Pharmacology Subcommittee and Parametric Tolerance Interval Test Workgroup.
You may also be interested in...
FDA’s proposal for relabeling of antihypertensive agents is based on prior recommendations by the committee that information on cardiovascular outcomes related to blood pressure lowering be included as class labeling.
FDA’s Oncologic Drugs Advisory Committee will meet in Atlanta to review Bristol’s multi-targeted kinase inhibitor dasatinib for two leukemia indications.
FDA’s Psychopharmacologic Drugs Advisory Committee rules safety for modafinil product in children with attention deficit/hyperactivity disorder has not been adequately demonstrated.